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100% of patients with CMV viremia and no CMV gut disease
were lymphopenic. There did not appear to be any associa-
tion between CMV PCR copy number and absolute lympho-
cyte count (r¼0.016; p¼0.49). There was no apparent pattern
or relationship between CMV PCR copy number and degree
of cytopathic changes on intestinal biopsy.
Conclusion: We hypothesized that all patients with gut-
associated CMV disease would have corresponding CMV
viremia. One patient with biopsy-proven disease had nega-
tive CMV PCR, so we are evaluating for potential sources of
false positivity because gut-conﬁned CMV (CMV disease
without CMV viremia) is relatively uncommon in the HSCT
setting. Our data support that a lack of CMV viremia does not
rule out gut-associated CMV disease and that intestinal bi-
opsy by EGD or colonoscopy is warranted in this patient
population.389
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Patients with end stage renal disease (ESRD) historically have
not been offered allogeneic hematopoietic cell trans-
plantation (HCT) because of the presumed high risk of
toxicity. Use of nonmyeloablative (NMA) conditioning regi-
mens has made allogeneic HCT a viable option for patients
with variety of baseline medical comorbidities. We report
our experience with NMA allogeneic HCT for patients with
ESRD who were on hemodialysis (HD) or peritoneal (PD)
before receiving NMA allogeneic HCT. We reviewed our
institutional database at Fred Hutchinson Cancer Research
Center from 1997-2013. Eight patients were on dialysis (7 on
HD and 1 on PD) before they received NMA allogeneic HCT
(Age: 13-67; F/M: 3/5). Six of eight patients (75%) were on
dialysis when the decision for NMA allogeneic HCT was
made. One patient was started on HD before the conditioning
regimen and one required HD after ﬁnishing the condition-
ing and before the infusion of stem cells. Etiologies of ESRD
included: Myeloma kidney (3), polycystic kidney disease (2),
hemolytic uremic syndrome secondary to E-coli infection (1),
acute tubular necrosis (ATN) (1) and acute obstructive kidney
injury (AKI) (1). Four patients (50%) had previously received
an autologous transplant (as part of an auto/allo tandem
approach). Primary diagnosis included multiple myeloma
(n¼4), NHL (n¼2) MDS/MPN (n¼1), WiskotteAldrichTable
Results of treosulfan use in conditioning in children vs adults
Children




3y OS ALL-51%, AML-46%,
inherited disorders-80%, hemoglobinopath
Other 3y EFS ALL-39% AML-40%syndrome (n¼1). The conditioning regimen included Flu-
darabine/2GyTBI (n¼3), 2GyTBI (n¼1), Fludarabine/
Melphalan/2GyTBI (n¼1) and Fludarabine/Cyclophospha-
mide/2GyTBI (n¼1). Fludarabine and Melphalan were
administered after dialysis but with no dose reduction.
Immunosuppression included Mycophenolate mofetil with
cyclosporine (n¼5) or Tacrolimus (n¼3). Seven of eight pa-
tients died during the follow-up period (median 10.1; range
0.2-84.6 months). Two patients died within 2 weeks after
transplant and neither was on dialysis at the time of referral
for HCT. One had progressive Mantle cell lymphoma and was
started on HD 7 days before the HCT because of obstructive
AKI secondary to abdominal lymphadenopathy and the
second patient had a diagnosis of multiple myeloma and
required HD because of ATN after the conditioning regimen
before stem cell infusion. This patient died from multi-sys-
tem organ failure secondary to conditioning regimen-related
toxicities (Flu/Mel/TBI). All other 7 patients survived for a
median of 11.5 months (range 3.8 e 84.6). Causes of death
included: CMV pneumonia, fungal CNS infection, uncon-
trolled bleeding during open heart surgery, relapse, and
sepsis. One patient is still alive 3.8 months post auto/allo
HCT. In conclusion, review of these cases indicates that NMA
allogeneic SCT for patients with ESRD on dialysis at the time
of referral did not lead to adverse outcomes but initiation of
dialysis shortly before HCT was associated with early mor-
tality after transplant.390
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Objective: The published literature was reviewed to assess
the impact of treosulfan for conditioning before allogeneic or
autologous SCT to identify possible differences between
children and adults with respect to toxicity, acute or chronic
graft versus host disease (a/cGVHD), treatment related
mortality (TRM), overall survival (OS), disease free survival
(DFS).
Material and Methods: Pediatric (patients aged <18 years)
data originated from EBMT megaﬁle report (EBMT Annual
Meeting 2012) and 1 study of 28 patients from India. Adult
data originated from 34 studies from European countries
(Germany, Poland, Italy, France, Finland, Italy), Israel (4
studies, 119 patients) and USA (1 study, 60 patients). The
analysis was performed based on data published before
October, 1st, 2013. Pediatric data included 604 (521 allo + 83
auto) evaluable patients out of total 871 patients reported.Adults
) Gastro-intestinal II (up to 33%), III-IV (10-29%)
Median 23% (range 14-50)
Median 42% (range 16-72)
14-16%
ies-93%
Median 61% (range 36-85)
Median 2y DFS 55% (range 35-82),
RI 25% (range 15-36), 100d TRM 11.8%.
